ReadYourDNA

Midazolam (Versed)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Midazolam

What it is

Midazolam is a short-acting benzodiazepine that strengthens the calming effect of GABA in the brain. It is used for sedation before and during procedures and surgery, in intensive care, and as a mouth or nasal spray to stop prolonged seizures. It also blocks memory formation for a short time. It is sold as Versed, Hypnovel and Buccolam, among other names.

How genes come into it

Midazolam is broken down almost entirely by CYP3A4 and CYP3A5, so completely that it is the standard test substance for measuring CYP3A activity in research. Studies have looked at CYP3A4, CYP3A5 and the vitamin D receptor gene VDR, which regulates CYP3A4, for its clearance; the effects found are modest. There is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Midazolam. Upload your DNA file to see which of these rows apply to you.

Rated evidence (7 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

CYP3A5 CYP3A5*1, CYP3A5*3: Level 3. Metabolism/PK. 4.

CYP3A4 rs35599367: Level 3. Other: Neoplasms. 2.

POR rs1057868: Level 3. Other. 2.

CYP3A4 rs12721627: Level 3. Other. 1.

Metabolism (20 findings)

Studies of how quickly the body processes this medication.

CYP2C19 CYP2C19 poor metabolizers and intermediate metabolizers: CYP2C19 poor metabolizers and intermediate metabolizers is associated with decreased dose of fentanyl, meperidine or midazolam in people with sedation as compared to CYP2C19 normal metabolizer.

CYP3A4 CYP3A4*1, CYP3A4*22: CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.

CYP3A4 CYP3A4*1, CYP3A4*22: CYP3A4 *1/*22 is associated with increased concentrations of 1-hydroxymidazolam and midazolam in healthy individuals as compared to CYP3A4 *1/*1.

CYP3A4 CYP3A4*1, CYP3A4*22: CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Ativan (Benzodiazepines)

Benzodiazepines (class) (Benzodiazepines)

Byfavo (Benzodiazepines)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com